Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

November 8, 2022

OTC Pink Market US Health Care Biotechnology earnings 52 min

Earnings Call Speaker Segments

Brant Biehn

executive
#1

Good afternoon, everyone, and thanks for joining us on today's call. From Vaxart, we have with us Andrei Floroiu, our Chief Executive Officer; Dr. Sean Tucker, our Founder and Chief Scientific Officer; and Dr. James Cummings, our Chief Medical Officer. Before we begin, I want to remind all of you that on this conference call, forward-looking statements may be made by Vaxart, including statements regarding the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. A number of important factors could cause actual results to differ materially from those discussed in these forward-looking statements, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic and other risks described in the Risk Factors section of Vaxart's most recently filed Annual Report on Form 10-K and other periodic reports filed with the SEC. No obligation is undertaken by Vaxart to update any forward-looking statements after this call. I'll now turn the call over to Andrei Floroiu. Andrei?

Cezar Floroiu

executive
#2

Thank you. And I appreciate all of you taking the time to be with us today; it's a pleasure to walk you through what we accomplished in the third quarter and to demonstrate how much transformation our oral vaccine platform could deliver. Let me begin with the financial piece that I think matters to our investors. Back in August, our shareholders gave the green light to our proxy proposal permitting an expansion of authorized shares from 100 million up to 250 million, a bump of 100 million. While that proxy vote was under way, a number of our retail holders worried that approving it would instantly cause heavy dilution. I want to set that worry aside; during the third quarter, once the proposal had passed, we put out just 1.8 million shares, which shows we kept our word. We'll stay extremely disciplined and pick our moments when it comes to new share issuance; so once more, my thanks go out to our shareholders for standing behind us, and I want to assure them their confidence was warranted. Now let me explain why the work happening at Vaxart has us so enthusiastic, and why Vaxart carries major potential both to reshape how infectious disease is fought around the world and to build real value for shareholders. Ever since the pandemic began, Vaxart has attracted considerable attention for its COVID-19 program, and rightly so. And although our COVID-19 program still holds substantial promise, even while overall interest in COVID-19 rises and falls, I'd like to focus on the larger picture here. Vaxart, as a genuine platform company, amounts to far more than its COVID-19 programs alone. This larger picture has 2 key components. First is our other lead clinical program, norovirus, which in our view is a massive opportunity for Vaxart. Second is the wider possibility that Vaxart's platform carries for overhauling the vaccination paradigm worldwide. My colleagues will share more about the norovirus opportunity, but let me show you this wider possibility of our technology. Not long ago, I received a formal invitation to the upcoming G20 Summit, specifically the B20 segment of the G20. So this week, I'm heading to Indonesia to talk with global political and business leaders about the part Vaxart's platform might play in global pandemic preparedness and in shaping the future architecture of healthcare. Now, small biotech companies typically don't receive G20 invitations. Vaxart did, though, thanks to the transformational potential of its technology, which speaks to one of the summit's key focus areas this year: how tomorrow's global healthcare architecture could help the world recover together, recover stronger, one of the mottos of this year's G20. And the Indonesian government is merely one among the governments eager to explore what role our platform might play in improving pandemic preparedness, for this pandemic, and future ones. So having gone over these updates—since I figure they'll help you get a clearer sense of the situation at Vaxart, and given the genuine enthusiasm around just how transformative our platform and programs could be—our <<inaudible>> points out what's plain to see: we're optimistic that such enthusiasm turns into real backing for Vaxart, though naturally nothing guarantees that outcome. So does all this enthusiasm hold up? We're convinced it does. Let me walk you through why Vaxart's platform looks so promising, based on the evidence we've gathered up to now. To start, our platform yielded the sole oral vaccine demonstrated to protect people from the respiratory pandemic virus just as effectively as a live injectable—an extraordinary finding. A tablet swallowed with water offered the same protection as a commercial shot that has to be given via needle. What's more, the oral tablet achieved this through a completely distinct mechanism from the injectable. The serum antibody levels from Vaxart's vaccine came in at 6x to 10x lower than those from the injectable. Even so, protection matched it, likely since it additionally triggered cellular immunity. Let me repeat that: serum antibodies from Vaxart's vaccine were as much as 10x lower than the injectable's, and still protection was equal. This deserves emphasis, since in a world fixated on needles, people tend to judge our results through the same prism applied to injectables—fixating on serum data alone, while overlooking that other branches of the immune system, mucosal immunity included, contribute meaningfully to protection too. Next, evidence gathered across our various programs thus far indicates our candidates also provoke mucosal immunity, and that our platform could deliver benefits over injectables in 4 respects: wide cross-reactivity toward variants, less viral transmission, extended protection, and gentler tolerability. Progress on even a single one of those fronts would matter a great deal. Even so, what our data shows so far hints our candidates could plausibly deliver on all 4. Dr. Tucker will walk through that data more thoroughly, and it's now also detailed in our fresh investor deck, posted on our website; for the moment, let me just hit a few quick highlights. What strikes us as quite encouraging is that all 4 potential gains rest on not merely 1 but several data sets drawn from our programs and trials. Take cross-reactivity toward variants and other corona viruses—it appeared in both of our COVID-19 clinical trials, meaning 2 of them; lower transmission or viral shedding turned up in a flu and a COVID-19 study. Lasting protection or immune responses showed up in trials for flu, norovirus, and COVID-19. Up to now, the safety profile we've seen for the vaccine candidates built on our platform has been favorable, and that's backed by 15 clinical trials involving over 500 subjects. So our view is that the true value of what our platform can do ought to be judged from all the data together that we've generated across numerous programs, not from zooming in on just one program. Also, as I mentioned, what our platform could deliver goes well beyond whatever any one program might achieve, however much potential that program may hold. To wrap up, let me pull together the reasons we're so enthusiastic about Vaxart's position right now. A genuinely transformative opportunity, backed by expanding data across programs, finances that are profitable, a highly capable team, and major clinical readouts coming in 2023. Among those readouts are 2 human challenge studies during 2023 — one involving norovirus, and the other involving COVID-19. These catalysts matter a great deal, since challenge studies carry efficacy endpoints, which means evaluating whether vaccines can prevent infection, instead of merely examining immune responses. With that, I'll hand the call to Dr. Sean Tucker so he can walk through our latest data in greater depth. After that, James Cummings — Dr. James Cummings will cover our clinical trial program. Sean? 16 clinical trials with more than 500 subs.

Sean Tucker

executive
#3

Thanks for that, Andrei. You brought up something worth noting—there are several key ways our Vaxart platform stands apart. I'd like to add some additional detail from the data perspective. First off, the evidence so far suggests our approach might produce wider immunogenicity than what injectable alternatives can offer. As an example, when we ran the Phase I study on our S+N COVID-19 vaccine construct, nasal IgA responses targeting SARS-CoV-2 rose by at least 1.5 fold in 46% of participants, and all of those responses demonstrated potent cross-reactivity across every coronavirus strain we examined—including not just SARS-CoV-2, but also the beta and alpha families, which are fairly divergent. Beyond that, we observed that many individuals in this trial generated responses which remained elevated for up to twelve months. Additionally, we have shown meaningful cross-reactive T cell responses targeting SARS-CoV-2, and in particular, we demonstrated substantial CD8 T cells, which are notably harder to produce using adjuvants alone. That is a truly important detail regarding the T cell aspect. Let me now discuss our COVID-19 Phase II study, the one involving only the S protein, which reinforces the cross-reactivity point once again. When we looked at people who'd been vaccinated, their mucosal reactions also fought off other SARS-CoV-2 types and the variants. To illustrate, half the subjects showed a mucosal response against Wuhan, and as a matter of fact, 55% of those same subjects mounted a mucosal response against what I'd describe as the strain going around at present, Omicron BA.4 and BA.5. Essentially, every person in whom we generated a mucosal response to Wuhan likewise responded to the more current — or the strains in circulation today. Next, I want to explain one important benefit — an additional important benefit of our platform. We think it will generate immunity that lasts longer, and we expect that to go beyond whatever an injected vaccine can provide. You've probably seen reports about how long some injected vaccines hold up, particularly the mRNA shots for COVID-19 and the flu vaccine given by injection. With that in mind, let me walk you through a few key points from what we've gathered. During our initial Phase I study on norovirus, we saw fecal IgA responses increase and those responses stayed strong past the six-month mark. Then there's our flu challenge study, funded by BARDA, where our oral vaccine showed 39% protective efficacy against illness and 47 protective efficacy against infection. One thing to keep in mind: we checked for infection between 90 and 120 days following vaccination, rather than the 30-day window that challenge studies typically use. We examined this over a significantly longer period. Additionally, as I noted before, in the COVID-19 Phase I trial for S+N, we demonstrated nasal IgA responses that stayed elevated beyond one year. Finally, our norovirus study in elderly participants — data we shared this summer — showed IgA and IgG responses that remained elevated even past 200 days. A third distinguishing feature of our oral, or pill-based, vaccine platform is its potential to reduce or block transmission. The proposed mechanism involves inducing a mucosal IgA response, which prevents the virus from being passed on to others. If you get a powerful IgA mucosal response up in the nose, there's a chance that IgA could hold down shedding of a respiratory pathogen — maybe stopping the virus from getting out in a way that spreads it. Now I want to walk through several of the main things we found in our data. In our Phase II challenge study, with the analysis done by BARDA, the probability was 80% that our oral vaccine would reduce viral influenza shedding by more than a commercial influenza shot did, and this was a direct head-to-head comparison. Then in the COVID-19 study — research on hamsters that Duke University led — giving our vaccine candidate by mouth or into the nose restrained airborne transmission of SARS-CoV-2 to animals that hadn't been vaccinated, animals never exposed to any vaccine. I want to emphasize this idea one more time: our ability to reduce transmission provides a significant advantage in fighting COVID-19. The reason is that when you succeed at that, the pace at which the virus moves among people can be slowed, meaning fewer people get sick at the same time. As a result, hospitals and other essential resources for caring for patients don't get stretched beyond capacity. And when transmission drops sufficiently that r not is below 2, the virus will essentially die out. Time after time, Vaxart has built a compelling argument for our oral pill vaccine technology and for the massive potential value it offers both to society and to shareholders. In mucosal vaccines, we're ahead of a lot of our competitors in the U.S., and we're committed to completing the job of getting pill-based vaccines to people everywhere. Beyond that, since our products don't need expensive cold chain storage, the hundreds of millions of individuals in developing countries who struggle to get injectable shots would finally be able to receive vaccines that save lives; in any nation that grants approval to our vaccines, the savings on cost and the benefits to the environment would be substantial; and we also have to consider the final step of vaccination in developed countries. We see tremendous potential in our mucosal vaccine approach, and our commitment is to turn that potential into products capable of addressing major public health needs while delivering returns for shareholders. At this point I'll turn things over to James Cummings — Dr. James Cummings — to walk through what we've accomplished lately, what comes next, and the milestones ahead for our COVID-19 and norovirus vaccine efforts. James?

James Cummings

executive
#4

Thanks, Sean. I want to start by discussing the clinical program for our COVID-19 vaccine. In early September, we shared top-line results from Part 1 of the Phase II trial for our S-only COVID-19 vaccine candidate, known as the 201 study. The candidate tested in the 201 study was designed using the viral spike protein from the original Wuhan strain of SARS-CoV-2. The findings from this trial make it clear the candidate was safe and well tolerated. These safety results align with what we saw from more than 500 participants in clinical trials of our tablet vaccine platform. Importantly, in the 201 study, few or no participants reported symptoms at the severity level that was frequently seen in trials of needle-injected vaccines. The secondary goal of the 201 study was to measure the immunogenicity of the S-only vaccine construct. Various evaluations show this candidate generates strong antibody and T cell responses and triggers both serum and mucosal immunity. As for what comes next, we have a number of key near-term milestones in our COVID-19 vaccine development efforts. The most efficient route to meaningful data for our COVID vaccine program is the Omicron COVID challenge, which hVIVO in the United Kingdom is currently developing. After their challenge model is validated, we will proceed with testing our most promising construct as a booster for individuals previously immunized with the needle-based vaccine; we are eager to obtain data on vaccine protective efficacy, impact on viral shedding, and correlates of immunity that will inform the studies that follow that challenge. I can assure you we are dedicated to advancing the candidate with the highest probability of success in a Phase III study. As for the study in India, that trial was designed more than a year ago, and our understanding of COVID and the landscape of potential solutions has shifted considerably. We continue to collaborate with the Indian government and engage in discussions with potential partners about the best next steps for our product in India. We look forward to the COVID challenge with hVIVO in the U.K. to further refine our COVID program pathway. In June, we announced positive preliminary results from a Phase Ib trial of our norovirus vaccine candidate in participants aged 55 to 80 years, which demonstrated stimulation of robust immune responses across all doses with a dose-dependent production of IgA antibody-secreting cells. We are very enthusiastic about these findings, since they highlight the strength of our vaccine technology approach. Also, because adults over the age of 65 years are particularly susceptible to norovirus infection, with 7.5% of this population infected every year. The data collected so far indicates that our norovirus vaccine could potentially offer protection against norovirus across a very broad age range. Building on the data generated to-date, we expect to now launch a Phase II trial of a bivalent norovirus vaccine. This vaccine contains 2 norovirus proteins, which may stimulate even more robust immune responses than we've observed with our monovalent candidate. Shortly, we will have a pre-specified futility analysis from our study. Should that come back positive, we anticipate sharing preliminary data from our ongoing Phase II norovirus challenge study in late first quarter or early second quarter of 2023; we're genuinely thrilled about what lies ahead and the upcoming milestones across our clinical trials, and we'll keep showing the transformative potential of our oral vaccine platform. At this point, I'll hand the call back to Andrei for some closing remarks, Andrei?

Cezar Floroiu

executive
#5

James, thank you — and Sean as well — for walking us through the clinical data, the progress we've made, and some of the important milestones that lie ahead. Now, prior to opening things up for questions, I'd like to offer a few remarks regarding where we stand on cash and what's coming up on the milestone front. Our press release noted that on September 30, 2022, our cash and cash equivalents totaled $114.8 million. To wrap up, I'm glad to say we remain on schedule to deliver key updates on our promising pipeline programs across the rest of this year and into 2023. Everyone on our team is driven, deeply committed, and enthusiastic, and I feel that same excitement as we keep building momentum and move our oral pill vaccine platform forward. Going forward, our attention is on unlocking an entirely new way of approaching vaccination — one that genuinely could answer the difficulties posed by infectious diseases both longstanding and newly emerging, and could also address the inequities in vaccine access that we've seen throughout history. I appreciate each of you for being with us on today's call, and a special thank you to the investors whose support of our mission continues. At this point, we'll move into the Q&A part of the call. Operator?

Pete Stavropoulos

analyst
#6

Pete Stavropoulos here, filling in for Charles. Congrats on everything you accomplished during the quarter just ended. My question concerns the norovirus program. As I understand it, you intend to kick off Phase II testing of the bivalent vaccine candidate either in 4Q or 1Q '23. Could you give some sense of how large that trial will be and how long it will run? Also, are you going to assess immunogenicity, efficacy, or both, and in what ways would this trial be different from the norovirus studies you have already run?

Cezar Floroiu

executive
#7

Sean, would you like to field this one?

Sean Tucker

executive
#8

Right, Pete. So this trial is an immunogenicity study, with roughly 600 participants, if I recall the design correctly. It's going to be a rolling 2 to 1 allocation, involving 2 separate dose levels plus placebo. And once again, like I said earlier, the focus is immunogenicity, and my expectation is that we'd see the readout somewhere around the midpoint of next year. From what I understand, there aren't efficacy endpoints spelled out. That said, our hope is that this trial can essentially provide the foundation for approaching the FDA with an end of Phase II meeting.

Pete Stavropoulos

analyst
#9

Okay, then regarding the difficulty with the norovirus challenge study — could you give some kind of remark on how the enrollment is going? And will you be able to report that data in the first quarter of '23?

Sean Tucker

executive
#10

Yeah, it's coming in at a decent pace. We anticipate having data in Q1 of the coming year.

Cezar Floroiu

executive
#11

Yeah, so Pete, we mentioned that we remain on schedule according to the guidance we gave before — that means sharing the data around the close of Q1 or the start of Q2 next year.

Pete Stavropoulos

analyst
#12

All right. And actually, going back to that Phase II we talked about just a moment ago, what factors are controlling whether it moves forward? Also, have the necessary materials for that study actually been produced?

Cezar Floroiu

executive
#13

I'm not aware of any factors holding things up. Once more, we've stated publicly that things remain on schedule, with the intention of kicking off at the close of Q4 or the beginning of Q1 this year.

Pete Stavropoulos

analyst
#14

All right. So a question regarding the COVID program — there's information available, plus authorizations for boosters targeting Omicron specifically. Even though the vaccine platforms are quite different, in what way does this affect how you're thinking about your program, and which candidates will you be moving ahead?

Sean Tucker

executive
#15

Yeah, I mean, clearly there are certainly individuals who have finished with Omicron-specific shots. My view is that what's out there is somewhat mixed, in terms of the — that matters. Once again, what we committed to doing was to examine results from our Phase I, S and N, and Phase II S-only, and also to look at a few of these new constructs, then make choices regarding how to proceed with the following steps. Something I wanted to highlight is that in that Phase II study, we observed some potent cross-reactive responses toward Omicron, in both serum and mucosa, and that definitely has some influence on us as we decide how to — the next steps in evaluating efficacy in that Omicron challenge. Clearly, that would be an excellent initial step or subsequent step for the program — to test our vaccines and demonstrate not just that they could be protected in a challenge model, but whether they — what the correlates of protection might result from the mucosal vaccine.

Cezar Floroiu

executive
#16

Let me just jump in with one more point. As everyone is aware, the main weakness of shots given by injection is that they look backward, in a sense. They're built to target a version of the virus from the past, correct? That's part of why, I believe, the take-up for the new Omicron or bivalent shots has been so weak — particularly in this region, though we genuinely don't know how well they will shield people from variants that are still emerging. With mucosal immunity, though, we have a chance to show cross-reactivity and possibly to show that swapping out vaccines isn't necessary when variants shift; as a result, you escape that endless loop of chasing a pandemic that mutates quicker than our ability to immunize.

Pete Stavropoulos

analyst
#17

Understood. I appreciate the extra detail, and I'm certainly eager to see results come in from the human challenge trials.

Sahil Kazmi

analyst
#18

Hello, Sahil Kazmi here, filling in for Mayank, with a handful of questions. I truly value the thorough update. And perhaps building on what was just asked — given that BA.5 now accounts for under 40% of cases, roughly, while BQ.1 is becoming more common — I'm just wondering, how much progress have you and your collaborators made toward determining the virus dose to be used in the challenge study?

Cezar Floroiu

executive
#19

I'm not sure — hello, this is — all right, Sean, why don't you handle that one.

Sean Tucker

executive
#20

Yeah, I don’t — yeah, our — at this moment, what our — the thing we’re doing is, we are definitely examining a BA.5 through the lens of an Omicron challenge, since we believe that gives us more useful information when it comes to truly putting the vaccine to the test. You’re correct, BQ is emerging now, and it might matter a great deal. And once again, here’s what we’ll do: we’ll begin tracking our candidates and how their immune responses vary when exposed to those variants too. One point worth mentioning, which Andrei raised before, is that we’ve observed our vaccine appears to perform pretty well against the Omicron BA.4, BA.5, and my expectation is that this will hold, it will look fine, against the BQ as well.

Sahil Kazmi

analyst
#21

Great; and moving on to the norovirus program, plus that challenge study we anticipate seeing in early next year. Could you shed some light on what the bar for a highly appealing profile would be? Perhaps framing it against what — some of your competitors in this space have done?

Sean Tucker

executive
#22

Absolutely, I'll handle this one. One key point, naturally, is that since we're relying on challenge studies, we're administering extremely, extremely large quantities of virus, so what we'd expect is that, will the challenge findings come out as some level of percent efficacy sitting on the, as I'd describe it, lower side, somewhere around 40% to 60%. That said, we have no — it might turn out greater too, but our — and once more, there's just — with the single challenge study that's been published and was successful for LigoCyte and the G11, that was conducted a number of years back, and I think that vaccine's efficacy was roughly 40 something percent; so once more challenge models are wonderful for the purpose of grasping, can your vaccines are protective, and what are the correlates that they use are employing a fairly substantial dose within that process?

Sahil Kazmi

analyst
#23

That's excellent, and I genuinely value the extra detail you provided.

Sean Tucker

executive
#24

I'm hoping that addresses what you were asking.

Sahil Kazmi

analyst
#25

Absolutely, absolutely, that's wonderful. Congrats on everything you've accomplished. Thanks for letting us ask. And good luck, Andrei, at the G20.

Cezar Floroiu

executive
#26

Thanks a lot.

Shubhendu Sen Roy

analyst
#27

Sir, you're probably aware that Arcturus Holdings just made public a partnership with CSL Seqirus — a vaccine company operating worldwide — aimed at creating and bringing to market self-amplifying mRNA vaccines. With that in mind, I was simply curious: would you say this signals growing interest in newer vaccine platforms among multinational corporations? In other words, how do you view it?

Cezar Floroiu

executive
#28

Yeah, this is Andrei speaking. It certainly does, in my view. And in case you looked at that deal, it concerned COVID, plus influenza, and it had a — how should I put it — pandemic preparedness focus. And pandemic preparedness, I'd say, is a topic appearing rather frequently these days, at least when we talk with different government and governmental bodies. So interest from investors in COVID specifically might wax and wane; however, when you speak with healthcare bodies and governments, I believe there's greater recognition that we must be more ready for potential future waves of COVID, but in particular — or perhaps more crucially — for pandemics yet to come. And more and more people understand that combating such pandemics using only the present generation of injectable vaccines isn't the optimal approach; hence, we require newer technologies. So I'm not sure whether that addresses what you asked.

Shubhendu Sen Roy

analyst
#29

Question from Shubhendu Sen Roy at Brookline Capital: Understood, I'll rejoin the queue later.

Cezar Floroiu

executive
#30

I'd also note that we're hopeful, and there are indications suggesting this will lead to greater interest from big biopharma players in the industry.

Brant Biehn

executive
#31

Much appreciated; at this point we'll move on to inquiries coming from retail investors. And although quite a few of these have come in, a portion of them, in my view, were already addressed through the questions submitted by analysts. I'm not sure whether we should hold off or elaborate, Andrei — the initial one asked about your strategy regarding possible collaborations, whether for the COVID-19 programs or the norovirus ones? I believe you touched on part of that. But would you like to say more about the response you provided a moment ago?

Cezar Floroiu

executive
#32

Okay, perhaps only slightly. I realize I'm pointing out something everyone can see, but as we've mentioned previously, we're constantly seeking the most effective ways to advance our platform and the various programs we have, and to boost shareholder value to its fullest. Therefore, we remain willing to consider collaborations, both within the United States and internationally.

Brant Biehn

executive
#33

Sean, I'll direct this next question to you. Where do you think Vaxart's COVID-19 candidates will land within the next-generation vaccine landscape? Go ahead, Sean.

Sean Tucker

executive
#34

Right. So, for people who haven't gotten immunized — maybe due to a fear of needles, or because of big logistical demands like cold chain medical supply and personnel — we definitely view our oral vaccine as something that can stand alone. Clearly, in the U.S. and elsewhere, many individuals have already had the shot or been infected, so across a lot of groups it will really serve as a booster. We view it as complementary to other vaccines. Now, we've definitely tested our product as a booster alongside the mRNAs. And we know that we're able to generate mucosal immune responses. And naturally, we believe it could be superior when it comes to producing mucosal cross-variant protection and possibly lowering transmission.

Brant Biehn

executive
#35

Great. Sean, this one is definitely headed your way too. Which additional infectious diseases might make strong prospects for the VACC platform down the road? And here's part two of that: are any particular target indications under consideration? Sean?

Sean Tucker

executive
#36

Okay, so clearly, we've done this before, and we're examining candidates that work mainly by triggering a viral-type response. That said, any vaccine able to gain something from a mucosal reaction strikes me as a genuinely strong target to pursue. As things stand, the vaccine programs we're running cover COVID-19, a respiratory pathogen, norovirus, enteric illnesses, influenza, respiratory RSV — that one also being respiratory — plus HPV, which is where we began, with something tied to cervical dysplasia. So once more, there are plenty of distinct targets available to us. And since this platform is so straightforward to work with, I won't spend time today going through many of the newer ones.

Brant Biehn

executive
#37

Thanks. Andrei, I believe you touched on this next point somewhat in your opening comments. But here's the question: how much cash runway do you have right now? Could you elaborate on that a bit?

Cezar Floroiu

executive
#38

Absolutely, Brant. During the third quarter, we closed with $114.8 million, and that gives us enough financial resources available to keep moving forward with our plans into the second half of 2023. That also covers making aggressive progress on our 2 lead clinical programs, norovirus and COVID-19. I'd like to frame this with a bit more context, though, so let me add 2 more points. To start, we think there are strong catalysts ahead in the near to medium term that could open up new or better funding opportunities for us. Secondly, if we ever determine it's the right move, there are levers available that we could use to extend this runway substantially.

Brant Biehn

executive
#39

Great. And, I suppose, Jim, you somewhat touched on this with the following question — what are the intentions regarding how the company gets funded — so perhaps just elaborate a bit more on that final bullet point, I guess.

James Cummings

executive
#40

Okay, so we kept looking into the different ways we could raise money. In my opening comments, I noted that talks with governments globally are still ongoing. In our view, the platform offers some pretty strong possible benefits compared with what's out there today. So we're still optimistic that at some stage those discussions could lead to funding — though naturally, there's no assurance of that. On top of that, we're exploring strategic partnership talks and, just as we have previously, tapping capital markets when the opportunity arises.

Brant Biehn

executive
#41

Thanks, we've received numerous COVID-19 questions, so I'll group several together to avoid too much repetition. Sean, I'll hand the first one to you: it asks for revised timing on the COVID-19 vaccine construct, what the decision date is, and the reasoning behind any shifts from what was previously expected.

Sean Tucker

executive
#42

Looking at the COVID vaccine construct, I'm not pleased with what we're seeing, and that's based on the data we have from Phase I S and N, along with the Phase II S-only, plus the more recent constructs that are in our research pipeline. Our intention is to proceed toward picking out which construct we'll use for the hVIVO COVID challenge study we have planned during the second half of 2023. Clearly, the potent cross-reactive responses directed at Omicron that our Phase II trial produced, together with the Wuhan — this trial is a Wuhan one — position us as a robust contender for that challenge study. And naturally, our belief is that this might let us accelerate the path of our development.

Brant Biehn

executive
#43

Great. And a related follow-up is essentially the same thing about — Andrei, let's hand this one to you, when does the challenge study get started? I believe you already touched on that, and Dr. Cummings touched on it too, but could you just repeat what our timeline is for the COVID challenge study? Are we still on schedule for the second half of 2023?

James Cummings

executive
#44

As a result, we stated that this trial would be launched during the latter portion of 2023. That remains on schedule, and additionally we're exploring options that could allow us to get that study underway at an earlier point. Therefore, as soon as we pinpoint those routes, we will clearly share the news.

Brant Biehn

executive
#45

Alright, so Sean, I'll direct this next question to you. It concerns the Phase IIa trial for COVID. Specifically, will there be any further insights released from that Phase IIa trial, going beyond the top-line data you announced in September? And if that's the case, when might that happen, Sean?

Sean Tucker

executive
#46

Sure, I anticipate that we'll be sharing fresh site — insights at the World Vaccine Congress in San Diego, which is coming up at the end of this month. And clearly, we're still looking at the data we've collected. And there are some new developments on the way, and once there's something interesting to put out, we'll put it out as soon as it's ready.

Brant Biehn

executive
#47

Andrei, the following question is headed your way, and it returns to the COVID challenge study; therefore, assuming the results from that COVID challenge study come back positive, would you foresee a quicker route toward vaccine approval?

Cezar Floroiu

executive
#48

Okay, that's a somewhat difficult thing to answer, since it truly hinges on what we see in the readout from that challenge study. Beyond that, it hinges on where the pandemic stands at that moment. So we're currently talking with a number of regulators — within the U.S., that means the FDA, and also beyond America — regarding worldwide use of our platforms directed at COVID-19; and as has become clear over the course of this pandemic, those regulators frequently arrive at divergent rulings, shaped not just by how strong the data are, but by how pressing their own unmet needs happen to be. So giving a real answer right now is genuinely hard, yet our confidence stays high that the upside of a needle free pill-based vaccine — one able to deliver a lot of the benefits we've described, durable protection, protection against various variants, and so on and so forth — remains a compelling proposition.

Brant Biehn

executive
#49

There are a few questions about the construct. Sean, you're going to get this one. For the first, you sort of touched on it with the previous question, and it asks you to build on what you said initially. Here's the question: which elements will shape the construct that you bring into the challenge study as well as a possible Phase III trial? Sean?

Sean Tucker

executive
#50

Yeah, at this point, I'd say the key factor when it comes to figuring out what to advance into the challenge study is how our mucosal IgA and neutralizing antibodies perform against Omicron, plus whether we can bring about a CD8 T cell response. On top of that, results from the trials where we're giving boosters to people who previously received an mRNA vaccine could give us extra insight into the immune profile, because by the time we get to the challenge, those individuals will already have had a vaccine added.

Brant Biehn

executive
#51

And great, and then the following question concerns Omicron — it's fairly close to something one of our analysts asked, so I'll pose it and perhaps you could build on the response you already provided. The question goes: assuming the present S construct does show cross-reactivity, what's the reason for beginning again with a construct aimed at Omicron? By the moment your construct is finished, wouldn't Omicron already be outdated? Sean?

Sean Tucker

executive
#52

Yeah, I believe we touched on that briefly. Perhaps I can put it more precisely. Naturally, we feel assured regarding how our current constructs cross-react. After all, we've demonstrated that in both the Phase I and Phase II trials. That said, to stay scientifically rigorous, we chose to examine the Omicron constructs, and we were set up to compare them against the others, at least at the pre-clinical stage. Again, we want to confirm that everything checks out and that we have the optimal vaccines moving forward. As for whether Omicron becomes obsolete—well, circumstances shift, but I still believe the Omicron family is the one appearing more frequently nowadays. So.

Brant Biehn

executive
#53

Okay, and moving on to the next question — Andrei, I'm turning it over to you. You already brought up that you'll be attending the G20, but I'd like you to say more about that. What I want to know is whether you think Vaxart will have a seat at the table when it comes to important government officials acknowledging that oral vaccines are needed. Andrei, go ahead.

Cezar Floroiu

executive
#54

Well, I'd like to think I gave you that answer, and clearly it's a yes. What we're seeing is that people are interested — at minimum, they want to talk about the ways our technology, which is pretty one-of-a-kind, could be useful during this pandemic and in future ones. So there are a number of nations we've been talking with, and those talks are still going on. And like I said, the focus isn't just COVID-19 — it goes past that, into pandemic preparedness. So these conversations are something we're still enthusiastic about; honestly, we feel privileged to be part of some of them, such as that invitation from the G20 that I brought up. And our hope is that down the road, some concrete backing will come our way. That said, as I noted when I opened, there's no guarantee these talks will amount to anything concrete. Still, what I can say to you at this moment is that many people respond to what we're saying about what our platform could do.

Brant Biehn

executive
#55

Great. Okay, Sean, this one was going to be handed back your way, and honestly, it's something people ask us about pretty regularly. What they want to know is this: in what ways does the oral tablet vaccine from Vaxart stand apart from the candidates given intra-nasally?

Sean Tucker

executive
#56

Yeah, that's a really solid question. So clearly, no one has ever run a direct head-to-head study pitting an intranasal candidate against an oral one — at least not for COVID-19, or honestly for anything, as far as I've been able to find. What's been published on intranasal vaccines is pretty limited, and to put it mildly, it hasn't looked all that impressive. From what I can gather, the immune response simply hasn't been very strong. Now, there's an aerosol vaccine — bear in mind, that one isn't sprayed up the nose; it gets breathed in through a device. China gave it the green light, and there are actually some papers out there — quite a few, in fact. I'd say our data holds up pretty well against it, with the obvious caveat that no direct comparison has been run. Especially when it comes to the Omicron response in serum mucosa, I'd argue what we have looks more convincing. And finally, sure, India and Russia have both gone ahead with intranasal vaccines. But nothing much has been published on those yet, and honestly, I have no idea what the approval was based on. To me that's a bit — well, it makes me wary. And I think all of us ought to be somewhat wary that these products got approved while the data still hasn't come out.

Brant Biehn

executive
#57

Alright, that's great. So, we've got a few questions here that overlap a bit. The first one is about what the outlook is for government funding, whether from the U.S. or internationally. Andrei, I believe you just addressed that. Then the next one asks for your views on the regulatory pathway. I'm not sure if there's anything you'd like to add beyond what you already said earlier. If there isn't, we can go to the next one.

Cezar Floroiu

executive
#58

Well, let me take a shot at that. I'm not sure I can improve on it. If it's — once more, speculation is difficult here. Different parts of the world could see different seasons. And they hinge on our performance in this challenge study and on what the perceived unmet need happens to be at that point; even so, we remain encouraged, since we have a highly differentiated platform in this case, and the data we've seen so far keeps being very encouraging.

Brant Biehn

executive
#59

I believe there's room for a few additional questions at this point. The next one concerns the workshop, Sean, so it will be directed to you, which you happen to be right in the middle of conducting. There's a mention of the November 7 to 8 workshop regarding mucosal vaccines for COVID where Dr. Tucker is giving a talk — it sounds like an amazing venue for teaching the scientific community along with the pandemic preparedness community about what Vaxart's candidates can offer and for generating some excitement around the company, and it would appear only natural to make investors and Wall Street aware of it. Yet I have not come across a press release, so please explain to me why this event matters. Sean, go ahead, if you would share your thoughts on the meeting you're just finishing up.

Sean Tucker

executive
#60

Absolutely. I believe you're talking about the NIH event titled Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities. That was a workshop rather than what you'd call a public conference, and I'd like to explain why it mattered. The positive part is that our vaccine generated human data strong enough to earn an invitation to that Prompt Invitation event. I got the chance to explain how our orally administered vaccine might trigger a protective response against a respiratory pathogen, to cover our flu study, and to describe the extremely potent nasal IgA response we observe. My sense is that it was received well, and I felt glad to have been asked to take part. Getting our information out there, I think, marked a significant step forward for us.

Brant Biehn

executive
#61

Great, and I have a few final norovirus questions for Sean. This one's directed at you, Sean. I believe we've touched on it already, but if you wouldn't mind going into a bit more detail. The question is whether we might get a look at any preliminary data from the noro challenge study before Q1, 2023?

Sean Tucker

executive
#62

Right, this trial is double-blind and placebo controlled, which is done so that bias can be prevented, and as for the data, we won't unblind it until the moment comes when it is ready to be unblinded. At that stage, we'll be in a position to see how well the vaccine performed and to truly grasp what the data shows.

Brant Biehn

executive
#63

All right. Now for the final question, which is about norovirus — after that challenge study, what might the upcoming steps for this program look like?

Sean Tucker

executive
#64

Absolutely, we've previously shared that we intend to proceed with a bivalent study. And once more, to ensure it's clear to everyone, we've addressed both the GI and GII.4 strains of norovirus, which caused most of the illness in adults for dose confirmation. The study should start late this year or early next year. So — this represents a significant advancement for the company, right before we reach the end of Phase II meeting with the FDA.

Brant Biehn

executive
#65

Alright, that wraps up our question-and-answer portion. That brings today's call to a close. I'd like to express a lot of gratitude to everyone who joined us on this call for spending their time hearing about the Vaxart story.

Sean Tucker

executive
#66

Thank you. Bye-bye.

Cezar Floroiu

executive
#67

Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.